Health
FDA developing regulatory guidance for medical devices using generative AI
The Food and Drug Administration plans to issue both general and specialized policy guidance to clarify oversight of AI-enabled medical technology.
The short version
- The FDA is working on a regulatory framework and formal policy guidance for medical devices incorporating generative artificial intelligence.
- Rick Abramson, director of the FDA's Digital Health Center of Excellence, stated the agency will issue both broad guidance and tailored policies for complex topics.
- The timeline for when the FDA will officially publish the guidance remains unspecified.
Key facts
- The FDA is constructing a regulatory plan to oversee medical devices that feature generative AI.[STAT]
- Rick Abramson, director of the FDA's Digital Health Center of Excellence, confirmed that the agency intends to issue formal policy guidance.[STAT]
- The planned releases will include overarching guidance on generative AI alongside specialized guidance targeting specific, high-complexity topics.[STAT]
What remains uncertain
- The exact publication dates and specific provisions of the upcoming FDA guidance documents have not been publicly detailed.[STAT]